一直亏损、未有产品上市，华熙生物入股这家医药公司！股价立马暴涨

Core Viewpoint - Huaxi Biological's strategic investment in Shengnuo Pharmaceutical, known as "China's first nucleic acid drug stock," has significantly impacted the stock price, which surged by 34.41% to HKD 4.57 per share as of September 8 [1] Group 1: Investment Details - Shengnuo Pharmaceutical announced a nearly 20% discounted share placement to raise HKD 208 million, with Huaxi Biological being a notable subscriber [2][4] - The share placement involves issuing 17.35 million new shares at HKD 12 per share, representing approximately 16.50% of the existing share capital [4][6] - Huaxi Biological, through its wholly-owned subsidiary, subscribed for HKD 138 million worth of shares, acquiring a 9.44% stake in Shengnuo [6] Group 2: Company Performance - Shengnuo Pharmaceutical has been in a loss-making state since its listing in 2021, with no product sales revenue generated as of June 30 this year [3][8] - The company focuses on RNA interference (RNAi) technology for new drug development, with its main candidate, STP705, currently in clinical development for two cancer indications [9] - Shengnuo's financials show total revenue of HKD 0.01 million for the first half of 2025, a decrease of 87.40% year-on-year, with total expenses of HKD 440 million [9] Group 3: Huaxi Biological's Performance - Huaxi Biological's performance has been under pressure, with a 19.57% decline in revenue to HKD 2.26 billion for the first half of 2025, and a 35.38% drop in net profit to HKD 220 million [11][12] - The company's largest revenue segment, skin science innovation, saw a 33.97% decrease in revenue to HKD 912 million [11] - The founder of Huaxi Biological has returned to implement reforms, including a strict anti-corruption policy and management restructuring [12]